|
|
Blood, 15 March 2008, Vol. 111, No. 6, pp. 2962-2972.
 Previous Article | Table of Contents | Next Article 
ASH 50TH ANNIVERSARY REVIEW
Multiple myeloma
Robert A. Kyle1, and
S. Vincent Rajkumar1
1 Division of Hematology, Mayo Clinic, Rochester, MN
Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Goldenberg
Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Clin. Cancer Res.,
April 15, 2009;
15(8):
2808 - 2817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Soriani, A. Zingoni, C. Cerboni, M. L. Iannitto, M. R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M. T. Petrucci, A. Guarini, et al.
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Blood,
April 9, 2009;
113(15):
3503 - 3511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al.
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
Blood,
April 2, 2009;
113(14):
3375 - 3382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al.
Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
Clin. Cancer Res.,
March 15, 2009;
15(6):
1998 - 2009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Berenson, O. Yellin, R. Patel, H. Duvivier, Y. Nassir, R. Mapes, C. D. Abaya, and R. A. Swift
A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Clin. Cancer Res.,
February 1, 2009;
15(3):
1069 - 1075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Brenner, A. Gondos, and D. Pulte
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Haematologica,
February 1, 2009;
94(2):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe, N. L. Harris, H. Stein, and P. G. Isaacson
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Blood,
December 1, 2008;
112(12):
4384 - 4399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zollinger, T. Stuhmer, M. Chatterjee, S. Gattenlohner, E. Haralambieva, H.-K. Muller-Hermelink, M. Andrulis, A. Greiner, C. Wesemeier, J. C. Rath, et al.
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Blood,
October 15, 2008;
112(8):
3403 - 3411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Taylor, J. Kriangkum, J. A. Pittman, M. J. Mant, T. Reiman, A. R. Belch, and L. M. Pilarski
Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny
Blood,
September 1, 2008;
112(5):
1894 - 1903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
